Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Derma Sciences: Close to Upgrading (DSCI, $4.54)

Investment Perspective

With the failure of its biotechnology drug candidate aclerastide, Derma Sciences is abandoning drug development efforts. The Company…
Read more…